About the Company
exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XGN News
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report
Exagen Inc. (NASDAQ:XGN) came out with a strong set of annual numbers that could potentially lead to a re-rate of the stock.
Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript
March 18, 2024 Exagen Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Exagen Inc.'s Fourth ...
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full ...
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.58 per share a year ago. These figures are ...
Exagen’s Strong Q4 Performance and Positive Outlook Justify Buy Rating
TD Cowen analyst Daniel Brennan maintained a Buy rating on Exagen (XGN – Research Report) today and set a price target of $7.00. Daniel ...
Exagen reports Q4 results
Net loss was $5.6 million, compared to a net loss of $14.4 million for the fourth quarter of 2022. Adjusted EBITDA was $(3.9) million for the fourth quarter of 2023 compared to $(13.4) million for the ...
Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates
Cresco Labs Inc. (CRLBF) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.03 per share a year ago.
Q4 2023 Exagen Inc Earnings Call
Greetings. Welcome to Exagen Inc's fourth-quarter 2023 earnings call. (Operator Instructions) Please note that this conference is being recorded. At this time, I'll hand the conference over to Ryan ...
Loading the latest forecasts...